<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37370001</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2172</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>27</Day></PubDate></JournalIssue><Title>BMC immunology</Title><ISOAbbreviation>BMC Immunol</ISOAbbreviation></Journal><ArticleTitle>Immunoprofiling of cytokines, chemokines, and growth factors in female patients with systemic lupus erythematosus- a pilot study.</ArticleTitle><Pagination><StartPage>13</StartPage><MedlinePgn>13</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">13</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12865-023-00551-6</ELocationID><Abstract><AbstractText>Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease affecting different organ systems. This study aimed to determine the concentrations of 30 different human cytokines, chemokines, and growth factors in human plasma to understand the role of these markers in the pathogenicity of SLE using Luminex Multiple Analyte Profiling (xMAP) technology. Plasma samples were obtained from patients with SLE (n&#x2009;=&#x2009;28), osteoarthritis (OA) (n&#x2009;=&#x2009;9), and healthy individuals (n&#x2009;=&#x2009;12) were obtained. High levels of TNF, IL-6, IFN-&#x3b3;, INF-&#x3b1;, IL-4, IL-5, IL-13, IL-8, IP-10, MIG, MCP-1, MIP-1&#x3b2;, GM-CSF, G-CSF, EGF, VEGF, IL-12, IL-1RA, and IL-10 was detected in SLE patients compared with the OA and healthy control groups. xMAP analysis has been used to address the differential regulation of clinical heterogeneity and immunological phenotypes in SLE patients. In addition, complete disease phenotyping information along with cytokine immune profiles would be useful for developing personalized treatments for patients with SLE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damiati</LastName><ForeName>Laila A</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-4746-0915</Identifier><AffiliationInfo><Affiliation>Department of Biology, College of Science, University of Jeddah, Jeddah, Saudi Arabia. ladamiati@uj.edu.sa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lab of Hematology, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia. ladamiati@uj.edu.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denetiu</LastName><ForeName>Iuliana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lab of Hematology, King Fahd Medical Research Centre, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahlas</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damiati</LastName><ForeName>Samar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pushparaj</LastName><ForeName>Peter Natesan</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Center of Excellence in Genomic Medicine Research, Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. peter.n.pushparaj@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, India. peter.n.pushparaj@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Immunol</MedlineTA><NlmUniqueID>100966980</NlmUniqueID><ISSNLinking>1471-2172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="Y">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chemokines</Keyword><Keyword MajorTopicYN="N">Growth factors</Keyword><Keyword MajorTopicYN="N">Luminex xMAP technology</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus; cytokines</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37370001</ArticleId><ArticleId IdType="pmc">PMC10303283</ArticleId><ArticleId IdType="doi">10.1186/s12865-023-00551-6</ArticleId><ArticleId IdType="pii">10.1186/s12865-023-00551-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiriakidou M, Ching CL. Systemic Lupus Erythematosus. Ann Intern Med. 2020;172:ITC81&#x2013;ITC96. doi: 10.7326/AITC202006020.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules vol.&#xa0;11 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301935</ArticleId><ArticleId IdType="pubmed">34206696</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 432595 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196871</ArticleId><ArticleId IdType="pubmed">22028588</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasselt M, Kippenhahn A, Baerwald C, Pietsch C, Seifert O. Relationship between cytomegalovirus prevalence and markers of disease activity in systemic lupus erythematosus. Rheumatology. 2022;61:1288&#x2013;90. doi: 10.1093/rheumatology/keab811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab811</ArticleId><ArticleId IdType="pubmed">34718424</ArticleId></ArticleIdList></Reference><Reference><Citation>et al. Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci. &amp; Med. 6, e000365 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937422</ArticleId><ArticleId IdType="pubmed">31921432</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271&#x2013;7. doi: 10.1002/art.1780251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780251101</ArticleId><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005;31:245&#x2013;54. doi: 10.1016/j.rdc.2005.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2005.01.009</ArticleId><ArticleId IdType="pubmed">15922144</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, et al. Derivation and validation of the systemic Lupus International collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;86. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ani&#x107; F, Zuvi&#x107;-Butorac M, Stimac D, Novak S. New classification criteria for systemic lupus erythematosus correlate with disease activity. Croat Med J. 2014;55:514&#x2013;9. doi: 10.3325/cmj.2014.55.514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3325/cmj.2014.55.514</ArticleId><ArticleId IdType="pmc">PMC4228292</ArticleId><ArticleId IdType="pubmed">25358884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sippl N, et al. Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. Clin Exp Immunol. 2021;205:44&#x2013;52. doi: 10.1111/cei.13585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13585</ArticleId><ArticleId IdType="pmc">PMC8209560</ArticleId><ArticleId IdType="pubmed">33576004</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuyama T, Tsokos GC, Moulton VR, Aberrant. T cell signaling and subsets in systemic Lupus Erythematosus. Front Immunol vol. 9 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5967272</ArticleId><ArticleId IdType="pubmed">29868033</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A. Anticytokine therapies in systemic lupus erythematosus. Immunotherapy. 2010;2:575&#x2013;82. doi: 10.2217/imt.10.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt.10.29</ArticleId><ArticleId IdType="pmc">PMC2929574</ArticleId><ArticleId IdType="pubmed">20636010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez LA, Ugarte-Gil MF, Alarc&#xf3;n GS. Systemic lupus erythematosus: the search for the ideal biomarker. Lupus. 2020;30:181&#x2013;203. doi: 10.1177/0961203320979051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320979051</ArticleId><ArticleId IdType="pubmed">33307987</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol. 2009;23:507&#x2013;23. doi: 10.1016/j.berh.2009.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2009.01.008</ArticleId><ArticleId IdType="pmc">PMC2727983</ArticleId><ArticleId IdType="pubmed">19591781</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin S, Yu C, Yu B. Changes of serum IL-6, IL-10 and TNF-&#x3b1; levels in patients with systemic lupus erythematosus and their clinical value. Am J Transl Res. 2021;13:2867&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8129414</ArticleId><ArticleId IdType="pubmed">34017450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y-R, Hsing C-H, Chiu C-J, Huang H-Y, Hsu Y-H. Roles of IL-1 and IL-10 family cytokines in the progression of systemic lupus erythematosus: friends or foes? IUBMB Life. 2022;74:143&#x2013;56. doi: 10.1002/iub.2568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iub.2568</ArticleId><ArticleId IdType="pubmed">34668305</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzeszotarska E et al. IL-1&#x3b2;, IL-10 and TNF-&#x3b1; polymorphisms may affect systemic lupus erythematosus risk and phenotype. Clin Exp Rheumatol (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35084314</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, Oke V. Cytokines as biomarkers in systemic Lupus Erythematosus: value for diagnosis and drug therapy. Int J Mol Sci. 2021;22:11327. doi: 10.3390/ijms222111327.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111327</ArticleId><ArticleId IdType="pmc">PMC8582965</ArticleId><ArticleId IdType="pubmed">34768756</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J, et al. Cytokine clusters as potential diagnostic markers of disease activity and renal involvement in systemic lupus erythematosus. J Int Med Res. 2020;48:300060520926882. doi: 10.1177/0300060520926882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0300060520926882</ArticleId><ArticleId IdType="pmc">PMC7271280</ArticleId><ArticleId IdType="pubmed">32489126</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco Y, et al. Cytokine and autoantibody clusters interaction in systemic lupus erythematosus. J Transl Med. 2017;15:239. doi: 10.1186/s12967-017-1345-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-017-1345-y</ArticleId><ArticleId IdType="pmc">PMC5702157</ArticleId><ArticleId IdType="pubmed">29178890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds JA, et al. Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations. Arthritis Res Ther. 2018;20:173. doi: 10.1186/s13075-018-1666-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1666-0</ArticleId><ArticleId IdType="pmc">PMC6085716</ArticleId><ArticleId IdType="pubmed">30092845</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahlas S, et al. Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex multiple analyte profiling technology for precision medicine. Clin Exp Rheumatol. 2019;37:112&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29998825</ArticleId></ArticleIdList></Reference><Reference><Citation>Cigni A, et al. Interleukin 1, interleukin 6, Interleukin 10, and Tumor Necrosis factor &#x3b1; in active and quiescent systemic Lupus Erythematosus. J Investig Med. 2014;62:825LP&#x2013;829. doi: 10.2310/JIM.0000000000000085.</Citation><ArticleIdList><ArticleId IdType="doi">10.2310/JIM.0000000000000085</ArticleId><ArticleId IdType="pubmed">24987977</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H, et al. TNF-&#x3b1; and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Lupus Sci Med. 2018;5:e000260. doi: 10.1136/lupus-2018-000260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000260</ArticleId><ArticleId IdType="pmc">PMC6018889</ArticleId><ArticleId IdType="pubmed">29955370</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle CE, et al. Large-scale analysis of tumor necrosis factor &#x3b1; levels in systemic lupus erythematosus. Arthritis Rheum. 2012;64:2947&#x2013;52. doi: 10.1002/art.34483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34483</ArticleId><ArticleId IdType="pmc">PMC3396783</ArticleId><ArticleId IdType="pubmed">22488302</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang N, et al. Expression profile of PU.1 in CD4(+)T cells from patients with systemic lupus erythematosus. Clin Exp Med. 2021;21:621&#x2013;32. doi: 10.1007/s10238-021-00717-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-021-00717-9</ArticleId><ArticleId IdType="pubmed">33966135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi S, Habibagahi Z, Heidari M, Abdollahpour-Alitappeh M, Karimi MH. Effects of combined aerobic and anaerobic exercise training on cytokine profiles in patients with systemic lupus erythematosus (SLE); a randomized controlled trial. Transpl Immunol. 2022;70:101516. doi: 10.1016/j.trim.2021.101516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trim.2021.101516</ArticleId><ArticleId IdType="pubmed">34922023</ArticleId></ArticleIdList></Reference><Reference><Citation>Molnar V et al. Cytokines and Chemokines involved in Osteoarthritis Pathogenesis. Int J Mol Sci 22, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8431625</ArticleId><ArticleId IdType="pubmed">34502117</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafouri-Fard S, Shahir M, Taheri M, Salimi A. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine. 2021;146:155640. doi: 10.1016/j.cyto.2021.155640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155640</ArticleId><ArticleId IdType="pubmed">34252872</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshio T, et al. IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. Lupus. 2016;25:997&#x2013;1003. doi: 10.1177/0961203316629556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316629556</ArticleId><ArticleId IdType="pubmed">26846690</ArticleId></ArticleIdList></Reference><Reference><Citation>Novikov A, et al. Cytokine profiles in systemic Lupus Erythematosus and Rheumatoid Arthritis. Ann Rheum Dis. 2016;75:907LP&#x2013;907. doi: 10.1136/annrheumdis-2016-eular.3130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-eular.3130</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong DJ, Whitehead EM, Crockard AD, Bell AL. Distinctive effects of G-CSF, GM-CSF and TNFalpha on neutrophil apoptosis in systemic lupus erythematosus. Clin Exp Rheumatol. 2005;23:152&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15895883</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanford SJ, Pepper JR, Burke-Gaffney A, Mitchell JA. Cytokine-activated human vascular smooth muscle delays apoptosis of neutrophils: relevance of interactions between cyclo-oxygenase-2 and colony-stimulating factors. FASEB J Off Publ Fed Am Soc Exp Biol. 2001;15:1813&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11481239</ArticleId></ArticleIdList></Reference><Reference><Citation>Enzler T, et al. Deficiencies of GM-CSF and Interferon &#x3b3; Link inflammation and Cancer. J Exp Med. 2003;197:1213&#x2013;9. doi: 10.1084/jem.20021258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20021258</ArticleId><ArticleId IdType="pmc">PMC2193978</ArticleId><ArticleId IdType="pubmed">12732663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngamjanyaporn P, et al. Predicting treatment response and clinicopathological findings in lupus nephritis with urine epidermal growth factor, monocyte chemoattractant protein-1 or their ratios. PLoS ONE. 2022;17:e0263778. doi: 10.1371/journal.pone.0263778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0263778</ArticleId><ArticleId IdType="pmc">PMC8912200</ArticleId><ArticleId IdType="pubmed">35271583</ArticleId></ArticleIdList></Reference><Reference><Citation>Avihingsanon Y, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int. 2006;69:747&#x2013;53. doi: 10.1038/sj.ki.5000132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ki.5000132</ArticleId><ArticleId IdType="pubmed">16518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak E, Wo&#x17a;niacka A, Sysa-Jedrzejowska A, Stepie&#x144; H, Robak T. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. Eur Cytokine Netw. 2001;12:445&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566625</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhya Z, et al. Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis. Lupus. 2019;28:713&#x2013;21. doi: 10.1177/0961203319845487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319845487</ArticleId><ArticleId IdType="pubmed">31046570</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrycek A, Janowska J, Cie&#x15b;lik P. Selected angiogenic cytokines in systemic lupus erythematosus patients. Autoimmunity. 2009;42:459&#x2013;66. doi: 10.1080/08916930902960339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930902960339</ArticleId><ArticleId IdType="pubmed">19811263</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak E, Wo&#x17a;niacka A, Sysa-Jedrzejowska A, Stepie&#x144; H, Robak T. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus. 2002;11:348&#x2013;55. doi: 10.1191/0961203302lu199oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu199oa</ArticleId><ArticleId IdType="pubmed">12139372</ArticleId></ArticleIdList></Reference><Reference><Citation>Manetti R, et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing th cells. J Exp Med. 1993;177:1199&#x2013;204. doi: 10.1084/jem.177.4.1199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.177.4.1199</ArticleId><ArticleId IdType="pmc">PMC2190961</ArticleId><ArticleId IdType="pubmed">8096238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nembrini C, Abel B, Kopf M, Marsland BJ. Strong TCR signaling, TLR ligands, and cytokine redundancies ensure robust development of type 1 effector T cells. J Immunol. 2006;176:7180&#x2013;8. doi: 10.4049/jimmunol.176.12.7180.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.12.7180</ArticleId><ArticleId IdType="pubmed">16751361</ArticleId></ArticleIdList></Reference><Reference><Citation>Uzrail AH, Assaf AM, Abdalla SS. Correlations of Expression Levels of a Panel of Genes (IRF5, STAT4, TNFSF4, MECP2, and TLR7) and Cytokine Levels (IL-2, IL-6, IL-10, IL-12, IFN-&#x3b3;, and TNF-&#x3b1;) with Systemic Lupus Erythematosus Outcomes in Jordanian Patients. Biomed Res. Int. 2019, 1703842 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6907047</ArticleId><ArticleId IdType="pubmed">31871930</ArticleId></ArticleIdList></Reference><Reference><Citation>H J Y, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci. 2010;107:204&#x2013;9. doi: 10.1073/pnas.0903158107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0903158107</ArticleId><ArticleId IdType="pmc">PMC2806746</ArticleId><ArticleId IdType="pubmed">20018660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizui M et al. IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4 &#x2013; CD8 &#x2013; IL-17&#x2013;Producing T Cells. J. Immunol. 193, 2168 LP &#x2013; 2177 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4135016</ArticleId><ArticleId IdType="pubmed">25063876</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage RJ, Macduff BM, Eisenman J, Paxton R, Grabstein KH. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol. 1995;154:483&#x2013;90. doi: 10.4049/jimmunol.154.2.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.154.2.483</ArticleId><ArticleId IdType="pubmed">7814861</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology. 2001;40:876&#x2013;81. doi: 10.1093/rheumatology/40.8.876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/40.8.876</ArticleId><ArticleId IdType="pubmed">11511756</ArticleId></ArticleIdList></Reference><Reference><Citation>Dooms H. Interleukin-7: fuel for the autoimmune attack. J Autoimmun. 2013;45:40&#x2013;8. doi: 10.1016/j.jaut.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831438</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert M, Miossec P. Interleukin-17 and lupus: enough to be a target? For which patients? Lupus. 2019;29:6&#x2013;14. doi: 10.1177/0961203319891243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203319891243</ArticleId><ArticleId IdType="pubmed">31791181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ndongo-Thiam N, Miossec P. A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis. Ann. Rheum. Dis. 74, 1629 LP &#x2013; 1631 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25902792</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond W, Ostli-Eilertsen G, Griffiths S, Nossent J. IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: evidence for a dual role. Eur J Rheumatol. 2017;4:29&#x2013;35. doi: 10.5152/eurjrheum.2017.16059.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2017.16059</ArticleId><ArticleId IdType="pmc">PMC5335884</ArticleId><ArticleId IdType="pubmed">28293450</ArticleId></ArticleIdList></Reference><Reference><Citation>du Toit R, et al. Serum cytokine levels associated with myocardial injury in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:2010&#x2013;21. doi: 10.1093/rheumatology/keaa540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa540</ArticleId><ArticleId IdType="pubmed">33221897</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>